Sign in

EW on NYSE

Edwards Lifesciences

Logo: Kopiersperre ( talk ), Public domain, via Wikimedia Commons5

American biotechnology company

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment.3 It employed about 14,000 people.1 Its shares trade on NYSE under the symbol EW.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1958Founded1

Compare with Steris, Zimmer Biomet Holdings or Align Technology, or pick any stock.

  • TickerEW on NYSE1
  • Industrymedical device1
  • HeadquartersIrvine1
  • Websitewww.EdwardsLifesciences.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business addressOne Edwards Way, Irvine, Ca 926146
  • Filer categoryLarge accelerated filer6
  • LEIYA13X31F3V31L8TMPR584
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 30937964

See how the biggest companies compare on our leaderboards

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

78.0%Gross margin9
20.8%Operating margin9
17.7%Net margin9
11.5%Revenue growth, 20259
10.4%Return on equity9
0.06×Debt to equity9
$1.3BFree cash flow9

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Transcatheter Aortic Valve Replacement brought in 74% of the revenue Edwards Lifesciences broke down this way in fiscal 2025.

  1. Transcatheter Aortic Valve Replacement$4.5B974%up 9% from 2024
  2. Surgical Heart Valve Therapy$1.0B917%up 5% from 2024
  3. Transcatheter Mitral And Tricuspid Therapies$550.6M99%up 56% from 2024
Products and services by year
Products and services202320242025
Transcatheter Aortic Valve Replacement$3.9B$4.1B$4.5B
Surgical Heart Valve Therapy$932.6M$981.3M$1.0B
Transcatheter Mitral And Tricuspid Therapies$197.6M$352.1M$550.6M

Business segments

United States brought in 58% of the revenue Edwards Lifesciences broke down this way in fiscal 2025.

  1. United States$3.5B958%up 11% from 2024
  2. Europe$1.5B925%up 15% from 2024
  3. Rest of World$652.3M911%up 14% from 2024
  4. Japan$354.7M96%up 4% from 2024
Business segments by year
Business segments202320242025
United States$2.9B$3.2B$3.5B
Europe$1.2B$1.3B$1.5B
Rest of World$531.1M$572.0M$652.3M
Japan$350.8M$339.8M$354.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue22¢$1.3B
  • Research and development18¢$1.1B
  • Selling, general and admin34¢$2.1B
  • Other costs5¢$278.6M
  • Income tax4¢$216.9M
  • Profit18¢$1.1B

Out of $6.1B in revenue.9

Where each dollar of operating cash went, fiscal 2025

  • Capital spending16¢$260.2M
  • Share buybacks56¢$893.4M
  • Kept or used elsewhere28¢$441.6M

Out of $1.6B of cash from operations.9

Financial statements

Revenue101112139$6.1B in 2025+40% since 2019
0$2.0B$4.0B$6.0B$8.0B2019: $4.3B$4.3B20192020: $4.4B$4.4B2020+1%2021: $5.2B$5.2B2021+19%2022: $4.5B$4.5B2022−15%2023: $5.0B$5.0B2023+12%2024: $5.4B$5.4B2024+9%2025: $6.1B$6.1B2025+12%
Gross profit101112139$4.7B in 2025+46% since 2019
0$2.0B$4.0B$6.0B2019: $3.2B$3.2B20192020: $3.3B$3.3B2020+2%2021: $4.0B$4.0B2021+21%2022: $3.7B$3.7B2022−6%2023: $4.0B$4.0B2023+8%2024: $4.3B$4.3B2024+7%2025: $4.7B$4.7B2025+10%
Operating income101112139$1.3B in 2025+10% since 2019
0$500.0M$1.0B$1.5B$2.0B2019: $1.1B$1.1B20192020: $897.6M$897.6M2020−22%2021: $1.7B$1.7B2021+88%2022: $1.5B$1.5B2022−11%2023: $1.3B$1.3B2023−13%2024: $1.4B$1.4B2024+5%2025: $1.3B$1.3B2025−8%
Net income12139$1.1B in 2025−29% since 2021
0$2.0B$4.0B$6.0B2021: $1.5B$1.5B20212022: $1.5B$1.5B2022+1%2023: $1.4B$1.4B2023−8%2024: $4.2B$4.2B2024+198%2025: $1.1B$1.1B2025−74%

Every line of the income statement as filed: the last 3 fiscal years, latest first.9

Period ending2025-12-312024-12-312023-12-31
Net sales$6.1B$5.4B$5.0B
Cost of sales$1.3B$1.1B$978.4M
Gross profit$4.7B$4.3B$4.0B
Selling, general, and administrative expenses$2.1B$1.8B$1.6B
Research and development expenses$1.1B$1.1B$962.9M
Intellectual property agreement and certain litigation expenses (Note 3)$325.4M$40.4M$203.5M
Change in fair value of contingent consideration liabilities (Note 13)-$12.5M$0-$26.2M
Restructuring charges, separation costs, and other (Note 4)$19.1M$61.0M$0
Intangible assets impairment charges$40.0M$0$0
Other operating income-$67.2M-$300.0K$0
Operating income$1.3B$1.4B$1.3B
Interest expense$20.4M$19.8M$17.6M
Interest income-$168.8M-$120.3M-$67.2M
Loss on impairment$146.9M$0$0
Other non-operating income, net (Note 18)-$7.2M-$68.9M-$13.9M
Income from continuing operations before provision for income taxes$1.3B$1.5B$1.4B
Provision for income taxes (Note 19)$216.9M$152.1M$152.4M
Net income from continuing operations$1.1B$1.4B$1.2B
Income from discontinued operations, net of tax$13.4M$2.8B$179.4M
Net income$1.1B$4.2B$1.4B
Less: Net loss attributable to noncontrolling interest-$4.1M-$4.9M-$3.0M
Net income attributable to Edwards Lifesciences Corporation.$1.1B$4.2B$1.4B
Continuing operations (in dollars per share)$2$2$2
Discontinued operations (in dollars per share)$0$5$0
Basic earnings per share (in dollars per share)$1.84$6.98$2.31
Continuing operations (in dollars per share)$2$2$2
Discontinued operations (in dollars per share)$0$5$0
Diluted earnings per share (in dollars per share)$1.83$6.97$2.30
Basic (in shares)584.8M shares597.7M shares606.7M shares
Diluted (in shares)585.8M shares599.3M shares609.4M shares

Compare Edwards Lifesciences with another company

Corporate structure

Edwards Lifesciences sits at the top of its group. 10 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Edwards Lifesciences

  • VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Edwards Lifesciences, latest Apr 29, 2026
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Edwards Lifesciences, latest Mar 26, 2026 (6 filings since Feb 9, 2022)
  • BlackRock Filed SCHEDULE 13G/A on Edwards Lifesciences, latest Oct 17, 2025 (4 filings since Feb 3, 2022)
  • Wellington Management Company Filed SCHEDULE 13G/A on Edwards Lifesciences, latest Aug 12, 2025 (2 filings since Nov 8, 2024)
  • Edwards Lifesciences Wilmington, Delaware, United States
    • Edwards Lifesciences (Switzerland) Subsidiary · Noviodunum, Switzerland
    • EDWARDS LIFESCIENCES (INDIA) PRIVATE LIMITED Subsidiary · Mumbai, India
    • Edwards Lifesciences (Japan) LLC Subsidiary · Japan
    • Edwards Lifesciences (U.S.) Inc. Subsidiary · Delaware, United States
    • Edwards Lifesciences Holding, Inc. Subsidiary · Delaware, United States
    • Edwards Lifesciences Sarl (Edwards Lifesciences Sàrl) Subsidiary · Nyon, Switzerland
    • Edwards Lifesciences Services GmbH Subsidiary · Germany
    • Edwards Lifesciences Technology Sarl (Edwards Lifesciences Technology Sàrl) Subsidiary · Irvine, California, United States
    • EDWARDS LIFESCIENCES WORLD TRADE CORPORATION Subsidiary · Wilmington, Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Edwards Lifesciences reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Land$152.4M9 Dec 31, 2025$123.9M9 Dec 31, 2024+23.0%
Machinery and equipment$739.8M9 Dec 31, 2025$689.4M9 Dec 31, 2024+7.3%
Computer equipment and software$75.0M9 Dec 31, 2025$83.4M9 Dec 31, 2024−10.1%
Construction in progress$301.2M9 Dec 31, 2025$244.0M9 Dec 31, 2024+23.4%
Property and equipment, before depreciation$2.7B9 Dec 31, 2025$2.5B9 Dec 31, 2024+7.3%
Accumulated depreciation$849.8M9 Dec 31, 2025$794.5M9 Dec 31, 2024+7.0%
Property and equipment, net$1.8B9 Dec 31, 2025$1.7B9 Dec 31, 2024+7.5%
Operating-lease assets (leased space)$102.7M9 Dec 31, 2025$98.2M9 Dec 31, 2024+4.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.9B9 Dec 31, 2025$3.0B9 Dec 31, 2024−3.5%
Marketable securities, current$1.3B9 Dec 31, 2025$930.7M9 Dec 31, 2024+38.4%
Debt securities available for sale$1.3B9 Dec 31, 2025$1.0B9 Dec 31, 2024+27.3%
Debt securities held to maturity$39.1M9 Dec 31, 2025$57.9M13 Dec 31, 2024−32.5%
Equity securities at fair value$185.5M9 Dec 31, 2025$119.1M9 Dec 31, 2024+55.8%
Stakes in other companies (equity method)$34.7M9 Dec 31, 2025$34.8M9 Dec 31, 2024−0.3%
Long-term investments$278.6M9 Dec 31, 2025$307.9M9 Dec 31, 2024−9.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.8B9 Dec 31, 2025$1.8B9 Dec 31, 2024−0.5%
Intangible assets, net (excluding goodwill)$1.1B9 Dec 31, 2025$1.2B9 Dec 31, 2024−4.1%
Finite-lived intangibles, gross$671.3M9 Dec 31, 2025$807.4M9 Dec 31, 2024−16.9%
Accumulated amortization$53.6M9 Dec 31, 2025$141.3M9 Dec 31, 2024−62.1%
Finite-lived intangibles, net$617.7M9 Dec 31, 2025$666.1M9 Dec 31, 2024−7.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.1B9 Dec 31, 2025$1.1B9 Dec 31, 2024+3.6%
Raw materials$196.6M9 Dec 31, 2025$241.1M9 Dec 31, 2024−18.5%
Work in process$252.9M9 Dec 31, 2025$236.2M9 Dec 31, 2024+7.1%
Finished goods$676.7M9 Dec 31, 2025$609.4M9 Dec 31, 2024+11.0%

Properties, in its own words

The locations and uses of our major properties are as follows:

North America

The rest of Item 2

Irvine, California · (1) · Corporate Headquarters, Research and Development, Regulatory and Clinical Affairs, Manufacturing, Marketing, Administration

Draper, Utah · (1),(2) · Manufacturing, Administration

Naperville, Illinois · (2) · Manufacturing, Administration

Central America

Cartago, Costa Rica · (1),(2) · Manufacturing, Administration

Europe

Nyon, Switzerland · (1) · Administration, Marketing

Prague, Czech Republic · (2) · Administration

Shannon, Limerick, Ireland · (1),(2) · Manufacturing

Valencia, Spain · (3) · Manufacturing

Asia

Singapore · (1),(2) · Manufacturing, Distribution, Administration

Tokyo, Japan · (2) · Administration, Marketing, Distribution

Shanghai, China · (2) · Administration, Marketing

Caesarea, Israel · (2) · Research and Development

(1) Owned property.

(2) Leased property.

(3) Under construction.

We believe our properties have been well maintained, are in good operating condition, and are adequate for current needs. We do not anticipate difficulty in renewing existing leases as they expire or in finding alternative facilities.

Item 2 of the 10-K filed Feb 25, 2026.17

The story

History

Edwards Lifesciences was originally founded by electrical engineer Miles "Lowell" Edwards in 1958, a graduate of Oregon State University. Edwards invented the first medically proven and adopted artificial heart valve. Dr. Albert Starr, a surgeon at the Oregon Health and Sciences University, is credited as the first to successfully implant the Starr-Edwards mitral valve in a patient in 1960. As a result of the successful heart implant, Edwards established manufacturing in Santa Ana, California the same year to continue his research in pulmonary devices.

Edwards' valves are still in operation today. An early patient lived a record 48 years with the implant before requiring a replacement.

Edwards was acquired by Baxter in 1985. It was spun off from Baxter in 2000.

In 2017, Edwards completed the acquisition of Valtech Cardio for $340 million. Also in 2017, Edwards acquired Harpoon Medical of Baltimore, Maryland for $100 million. Harpoon, founded in 2013, developed a minimally invasive heart surgery product for mitral valve repair to treat degenerative mitral regurgitation. At the time of the acquisition, the product was not available on any market.

On April 18, 2019, Edwards completed the acquisition of CAS Medical Systems of Branford, Connecticut for ~$100 million.

Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valve systems were FDA-approved for the treatment of patients at low risk for death or major complications associated with open-heart surgery on August 16, 2019. These products are used to treat patients with severe aortic stenosis without utilizing open-heart surgery.

In 2020, Edwards co-sponsored the Virtual ISPOR-FDA Summit centered on patient preference information in medical device regulatory decisions.

In December 2021, the FDA approved the SAPIEN 3 transcatheter valve in combination with the Alterra adaptive prestent for the treatment of severe pulmonary regurgitation.

Read the full text

In February 2024, the FDA approved Edwards' EVOQUE tricuspid valve replacement system, the first transcatheter therapy approved in the United States for the treatment of tricuspid regurgitation. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.

In June 2024, the company received FDA approval for a new implant designed to manage heart failure issues, called the Cordella pulmonary artery sensor.

In July 2024, Edwards made agreements with Affluent Medical for an equity stake, IP licensing and an exclusive option to acquire its Kephalios subsidiary. The same month, Edwards announced it would acquire Innovalve Bio Medical for approximately $300 million, and JenaValve Technology and Endotronix for $1.2 billion.

In August 2024, Edwards acquired JC Medical from Genesis MedTech, gaining its J-Valve transcatheter aortic valve replacement system for the treatment of aortic regurgitation.

In 2023, Edwards announced that its critical care business unit would be spun off into a separate entity. In June 2024 Edwards instead agreed to sell the unit to BD for $4.2 billion. The sale closed on September 3, 2024.

In May 2025, the FDA approved the SAPIEN 3 platform, including the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA valves, for the treatment of severe aortic stenosis in asymptomatic patients, marking the first FDA approval of TAVR therapy for this patient population.

In September 2025, Edwards completed the full acquisition of heart failure monitoring company Vectorious Medical Technologies.

In January 2026, the FDA approved the SAPIEN M3 mitral valve replacement system, the first transcatheter mitral valve replacement therapy using a transseptal approach to receive FDA approval for the treatment of mitral regurgitation.

Edwards Lifesciences Foundation

The Edwards Lifesciences Foundation launched in 2014 and supports programs designed to treat underserved people to reduce heart valve disease.

Since the initiative launched in 2014, Edwards and its foundation have contributed more than $100 million in financial and technology donations through "Every Heartbeat Matters" (EHM), reaching over 4 million underserved structural heart patients globally.

From Wikipedia’s article on Edwards Lifesciences, shared under CC BY-SA 4.0.7

Leadership

Who has led Edwards Lifesciences, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael A. Mussallem2006–2023
  2. Bernard J. Zovighian2023–now

Chair

  1. Michael A. Mussallem2006–2023

President

  1. Larry L. Wood2023
  2. Bernard J. Zovighian2023

Chief financial officer

  1. Thomas M. Abate2006–2013
  2. Scott B. Ullem2014–2026
  3. Theodora Mistras2026–now
197019801990200020102020
Board members and other officers (44)

Products and brands

Prior to September 2024, its products were categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and critical care. In September 2024, Edwards completed the sale of its Critical Care product group to BD. Since September 2024, its products are categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and implantable heart failure management (IHFM).

Transcatheter Heart Valve

The company's SAPIEN family of transcatheter aortic heart valves is made of bovine pericardial tissue mounted within a balloon-expandable, cobalt-chromium frame and is deployed via catheter. Edwards introduced the transcatheter heart valve replacement procedure to U.S. patients unable to undergo open-heart surgery with FDA approval of the SAPIEN transcatheter valve in 2011. The indication was expanded in November 2012 to include patients at a high risk for death or serious complications associated with open-heart surgery. In 2021, the FDA cleared Edwards’ SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for pulmonic heart valve replacement. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.

Transcatheter Mitral and Tricuspid Therapies

The Transcatheter Mitral and Tricuspid Therapies business segment develops transcatheter heart valve repair and replacement technologies to treat mitral and tricuspid valve diseases. In September 2022, the FDA approved Edwards' PASCAL Precision transcatheter valve repair system for the treatment of degenerative mitral regurgitation.

Surgical

The Surgical business segment involves the use of Edwards' RESILIA tissue technology, developed to help limit valve calcification. Edwards estimates that more than 450,000 patients around the world have either undergone SAVR or TAVR with an Edwards RESILIA valve.

Read the full text

Critical Care

Before its sale, the Critical Care business segment included pulmonary artery catheters, disposable pressure transducers and advanced hemodynamic monitoring systems. The portfolio also included a line of balloon catheter-based vascular products, surgical clips and inserts. In 2023, it was announced that the critical care business unit was to be spun off into its own entity, however in 2024 the critical care department was purchased by BD for $4.2 billion.

From Wikipedia’s article on Edwards Lifesciences, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Subsidiaries

Subsidiaries (Exhibit 21)

  • Edwards Lifesciences (Japan) LLC Japan8
  • Edwards Lifesciences (U.S.) Inc. Delaware8
  • Edwards Lifesciences Holding, Inc. Delaware8
  • Edwards Lifesciences LLC Delaware8
  • Edwards Lifesciences SAS France8
  • Edwards Lifesciences Services GmbH Germany8

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • CVG CONTROLLED INCDec 8, 1999 to Jan 21, 20006

Timeline

  1. Aug 28, 20268-K Executive or director change68
  2. Jul 23, 20268-K Results of operations69
  3. May 8, 20268-K Executive or director change; Shareholder vote70
  4. May 4, 20268-K Executive or director change; Regulation FD disclosure71
  5. Apr 23, 20268-K Results of operations72
  6. Feb 10, 20268-K Results of operations73
  7. Jan 12, 20268-K Regulation FD disclosure74
  8. Oct 30, 20258-K Results of operations75
  9. Oct 30, 20258-K Executive or director change; Regulation FD disclosure76
  10. Aug 19, 20258-K Other events77
  11. Aug 6, 20258-K Regulation FD disclosure78
  12. Jul 25, 20258-K Executive or director change79
  13. Aug 1, 2023New chief executive Bernard J. Zovighian becomes CEO18
  14. Jan 4, 2006New chief executive Michael A. Mussallem becomes CEO19
  15. Apr 3, 2000Went public Listed on NYSE1
  16. 1958Founded Founded1

Calendar

Coming up

  1. Nov 4, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported $0.67 a share, on Oct 30, 2025.80

When it reported results

  1. Jul 23, 2026Reported quarterly or annual results69
  2. Apr 23, 2026Reported quarterly or annual results72
  3. Feb 10, 2026Reported quarterly or annual results73
  4. Oct 30, 2025Reported quarterly or annual results75
  5. Jul 24, 2025Reported quarterly or annual results81
  6. Apr 23, 2025Reported quarterly or annual results82
  7. Feb 11, 2025Reported quarterly or annual results83
  8. Oct 24, 2024Reported quarterly or annual results84

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

670 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 43 major events, 445 insider forms, 13 large holders, 149 other. The latest 20:

  1. Oct 8, 20264 EDGAR
  2. Sep 14, 20264 EDGAR
  3. Sep 14, 20264 EDGAR
  4. Sep 11, 20264 EDGAR
  5. Sep 11, 20264 EDGAR
  6. Aug 31, 2026144 EDGAR
  7. Aug 31, 20264 EDGAR
  8. Aug 28, 2026144 EDGAR
  9. Aug 28, 20264 EDGAR
  10. Aug 28, 20268-K EDGAR
  11. Aug 26, 2026144 EDGAR
  12. Aug 26, 2026144 EDGAR
  13. Aug 26, 20264 EDGAR
  14. Aug 26, 20264 EDGAR
  15. Aug 11, 2026144 EDGAR
  16. Aug 11, 20264 EDGAR
  17. Aug 4, 2026S-8 EDGAR
  18. Aug 4, 202610-Q EDGAR
  19. Jul 30, 2026144 EDGAR
  20. Jul 30, 2026144 EDGAR

The 670 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

251 open-market trades by officers, directors and large owners since October 2021: 2 buys and 249 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 11, 2026Lippis Daniel J.CVP, TAVRSale619$87.51$54.2KForm 4
Aug 31, 2026Dahl Andrew M.SVP, Corporate ControllerSale544$91.06$49.5KForm 4
Aug 28, 2026Bruls AnnetteCVP, EMEACLASale2,644$89.98$237.9KForm 4
Aug 26, 2026Chopra DaveenCVP, TMTT, Surgical & IHFMSale31,800$91.02$2.9MForm 4
Aug 26, 2026Markowitz WayneCVP, JAPACSale1,240$91.47$113.4KForm 4
Aug 11, 2026Lippis Daniel J.CVP, TAVRSale619$92.03$57.0KForm 4
Jul 30, 2026Markowitz WayneCVP, JAPACSale146$86.03$12.6KForm 4
Jul 28, 2026Markowitz WayneCVP, JAPACSale9,628$85.06$819.0KForm 4
Jul 27, 2026Zovighian Bernard JCEOSale2,921$83.93$245.1KForm 4
Jul 10, 2026Lippis Daniel J.CVP, TAVRSale619$91.70$56.8KForm 4
Jun 30, 2026Lippis Daniel J.CVP, TAVRSale619$91.40$56.6KForm 4
Jun 17, 2026Zovighian Bernard JCEOSale523$87.92$46.0KForm 4
May 29, 2026Dahl Andrew M.SVP, Corporate ControllerSale568$86.08$48.9KForm 4
May 27, 2026BOBO DONALD E JRCVP,Strategy/Corp DevelopmentSale23,145$86.42$2.0MForm 4
May 22, 2026Chopra DaveenCVP, TMTT, Surgical & IHFMSale1,500$84.60$126.9KForm 4
May 18, 2026Lippis Daniel J.CVP, TAVRSale620$81.14$50.3KForm 4
May 15, 2026BOBO DONALD E JRCVP,Strategy/Corp DevelopmentSale17,968$81.96$1.5MForm 4
May 12, 2026Zovighian Bernard JCEOSale36,351$77.93$2.8MForm 4
May 11, 2026Markowitz WayneCVP, JAPACSale593$79.73$47.3KForm 4
May 4, 2026Lippis Daniel J.CVP, TAVRSale1,019$83.98$85.6KForm 4

All 251 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Mr. Zovighian$1.2M$17.5M89
2025Mr. Ullem$807.9K$6.1M89
2025Mr. Wood$635.9K$4.9M89
2025Mr. Chopra$671.0K$4.7M89
2025Mr. Bobo$759.8K$4.2M89
2025Ms. Brüls$726.6K$3.7M89
2024Chief Executive Officer and Director$1.1M$14.6M89
2024Corporate Vice PresidentChief Financial Officer$774.3K$5.3M89
2024Former Corporate Vice President and Group PresidentTranscatheter Aortic Valve Replacement and Surgical Structural Heart$778.5K$4.6M89
2023Chief Executive Officer and Director$972.8K$12.9M89
2023Corporate Vice PresidentChief Financial Officer$743.4K$5.9M89
2023Former Corporate Vice President and Group PresidentTranscatheter Aortic Valve Replacement and Surgical Structural Heart$763.2K$5.4M89

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.58,789,433$5.3B0.1%+6,198,500
Vanguard Capital Management LLC37,615,952$3.4B0.1%−111,840
Vanguard Portfolio Management LLC26,411,402$2.4B0.1%+4,384
State Street Corp26,321,940$2.4B0.1%+25,541
Jpmorgan Chase & Co22,783,175$2.1B0.1%+1,038,463
Wellington Management Group Llp16,827,967$1.5B0.3%−5,183,134
Geode Capital Management, LLC15,437,251$1.4B0.1%+2,303,474
Bank of New York Mellon Corp14,084,483$1.3B0.2%−2,653,065
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main13,002,965$1.2B0.9%+191,063
Ninety One UK Ltd12,337,502$1.1B2.5%−58,641
Aristotle Capital Management, LLC8,665,712$783.9M1.6%New
Fmr LLC8,435,949$763.1M0.0%−6,067,821
Norges Bank8,373,783$757.5M0.1%New
Alliancebernstein L.P.8,660,416$693.5M0.2%+5,193,061
Brown Advisory Inc7,365,987$666.3M1.0%+336,475
Bank Of America Corp /de/6,692,424$605.4M0.0%+2,809,005
Artisan Partners Limited Partnership6,625,703$599.4M1.0%+1,424,559
Morgan Stanley6,339,368$573.5M0.0%−721,508
Deutsche Bank Ag\5,710,284$516.6M0.2%−344,739
Arrowstreet Capital, Limited Partnership5,677,344$513.6M0.2%+3,786,485
Northern Trust Corp5,671,229$513.0M0.1%−153,140
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC5,488,643$496.5M0.1%+30,495
WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST4,800,000$434.2M4.8%No change
Goldman Sachs Group Inc4,549,113$411.5M0.0%−532,937
Legal & General Group Plc4,301,222$389.1M0.1%−148,332

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

28 trades disclosed by members of Congress, the latest 25. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 27, 2026Alan ArmstrongRepublican, SenateBuy$1,001 - $15,000−12.6%Report
Nov 19, 2025Josh GottheimerDemocratic, HouseSale$1,001 - $15,000+15.8%Report
May 12, 2025Jefferson ShreveRepublican, HouseSale$50,001 - $100,000+16.6%Report
Apr 21, 2025Bruce WestermanRepublican, HouseSale$1,001 - $15,000+25.0%Report
Apr 8, 2025Robert P. Bresnahan, Jr.Republican, HouseBuy$1,001 - $15,000−26.3%Report
Apr 7, 2025Jefferson ShreveRepublican, HouseBuy$15,001 - $50,000−27.5%Report
Mar 3, 2025Bruce WestermanRepublican, HouseBuy$1,001 - $15,000−10.9%Report
Aug 20, 2024Markwayne Mullin, SenatePartial sale$15,001 - $50,000+13.3%Report
Apr 11, 2024Mike KellyRepublican, HouseSale$1,001 - $15,000+54.3%Report
Dec 11, 2023Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−43.9%Report
Dec 4, 2023John R. CurtisRepublican, HouseSale$1,001 - $15,000+43.8%Report
Oct 3, 2023Markwayne Mullin, SenateBuy$1,001 - $15,000−58.6%Report
Sep 13, 2023Markwayne Mullin, SenateBuy$15,001 - $50,000−54.5%Report
Jun 21, 2023John R. CurtisRepublican, HouseBuy$1,001 - $15,000−82.4%Report
May 25, 2023Zoe LofgrenDemocratic, HouseSale$1,001 - $15,000+80.1%Report
Apr 26, 2023John R. CurtisRepublican, HouseBuy$1,001 - $15,000−91.8%Report
Apr 3, 2023Tommy TubervilleRepublican, SenateSale$1,001 - $15,000+82.4%Report
Mar 6, 2023Daniel S. GoldmanDemocratic, HouseBuy$15,001 - $50,000−80.9%Report
Sep 16, 2021Katherine M. ClarkDemocratic, HouseSale$1,001 - $15,000+100.8%Report
Sep 2, 2021Zoe LofgrenDemocratic, HouseBuy$1,001 - $15,000−98.5%Report
Aug 9, 2021Zoe LofgrenDemocratic, HouseBuy$1,001 - $15,000−98.8%Report
Jul 27, 2021Katherine M. ClarkDemocratic, HouseSale$1,001 - $15,000+97.0%Report
Mar 29, 2021Tommy TubervilleRepublican, SenateBuy$1,001 - $15,000−89.9%Report
Feb 16, 2021Peter Meijer, HouseSale$1,001 - $15,000+97.2%Report
Jan 28, 2021Peter Meijer, HousePartial sale$1,001 - $15,000+100.5%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Edwards Lifesciences is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREdwards Lifesciences Corp2
  • CIK0001099800
  • Employer ID (EIN)36-431661417
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company17
  • Incorporated inDelaware17
  • Fiscal year endsDecember 312
  • Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business addressOne Edwards Way, Irvine, CA 926142
  • Phone94925025002
  • Shares outstanding576,400,000 as of Jul 31, 202615
  • Public float$45.9B as of Jun 30, 202517
  • AuditorPricewaterhouseCoopers LLP, Irvine, California PCAOB ID 238; it also attests to the company’s internal control over financial reporting17
  • On EDGAR sinceDec 8, 19992
  • Filings2,612 in all: 4 (1,801), 8-K (204), 144 (104), SC 13G/A (85), 10-Q (80), 11-K (52), 3 (36), DEF 14A (26)2
    All 44 form types

    DEFA14A (26), 10-K (25), S-8 (25), SC 13G (23), 4/A (13), SD (13), UPLOAD (12), 5 (10), CORRESP (10), 424B3 (9), ARS (7), S-3ASR (6), 10-12B/A (5), SCHEDULE 13G/A (4), POS AM (3), PRE 14A (3), S-3/A (3), 10-Q/A (2), 424B2 (2), 424B5 (2), 424B7 (2), D (2), FWP (2), NT 11-K (2), S-3 (2), 10-12B (1), 10-K/A (1), 10-K405 (1), 3/A (1), 8-A12B (1), 8-K/A (1), CT ORDER (1), DEFR14A (1), NO ACT (1), SC 13D (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Feb 25, 2026
    Quarterly report (10-Q) Aug 4, 2026
    Proxy statement (DEF 14A) Mar 26, 2026
    Latest 8-K (8-K) Aug 28, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $1.00 per shareEWNew York Stock Exchange

From the cover page of the 10-K filed Feb 25, 2026 (Section 12(b) of the Exchange Act).17

Risk factors and legal proceedings

The risks Edwards Lifesciences names in Item 1A of its 10-K filed Feb 25, 2026: 28 risks under these headings, as written.17

  • Business and Operating Risks
  • Failure to successfully innovate and develop new and differentiated products in a timely manner and effectively market these products could have a material effect on our prospects.
  • Unsuccessful clinical trials or procedures relating to products could have a material adverse effect on our prospects.
  • If we or one of our suppliers or logistics partners encounters manufacturing, logistics, safety, or quality problems, our business could be materially adversely affected.
  • We operate in highly competitive markets, and if we do not compete effectively, our business will be harmed.
  • The success of many of our products depends upon certain key physicians, research institutions, and hospital systems.
  • We are subject to risks associated with public health crises.
  • We rely on third parties in the design, manufacture, and sterilization of our products. Any failure by or loss of a vendor could result in delays and increased costs, which may adversely affect our business.
  • Our use of, or our failure to effectively and timely utilize, emerging technologies, including AI, could adversely impact our business and financial results.
  • Failure to protect our information technology infrastructure and our products against cybersecurity attacks, network security breaches, service interruptions, or data corruption could materially disrupt our operations and adversely affect our business and operating results.
  • Our business and results of operations may be adversely affected if we are unable to recruit and retain qualified talent or are otherwise unsuccessful in the execution of our management succession plans.
  • Failure to successfully integrate acquired businesses, technologies or strategic alliances, or challenges related to the execution of acquisitions or divestitures, as well as liabilities or claims relating to such acquired businesses or divestitures, could adversely affect our business and results of operations.
The other 17 risks
  • We are subject to risks associated with the sale of our Critical Care product group.
  • Global Macroeconomic and Industry Risks
  • We may be adversely impacted by global economic, political and social conditions.
  • Our international operations subject us to certain business risks.
  • If government or other third-party payors decline to reimburse our customers for our products or impose other cost containment measures to reduce reimbursement levels, our ability to profitably sell our products will be harmed.
  • Continued consolidation in the health care industry could have an adverse effect on our sales and results of operations.
  • Legal, Compliance, and Regulatory Risks
  • Our inability to protect our intellectual property or failure to maintain the confidentiality and integrity of data or other sensitive company information, by cyber-attack or other event, could have a material adverse effect on our business.
  • Third parties may claim we are infringing their intellectual property, and we could suffer significant litigation or licensing expenses or be prevented from selling products.
  • Health care legislation and other regulations may adversely impact access to and demand for our products.
  • We and our customers are subject to healthcare legislation and other rigorous governmental regulations and we may incur significant expenses to comply with these regulations. In addition, failure to comply with these regulations could subject us to substantial sanctions and may impact our ability to sell our products in certain countries which could adversely affect our business, financial condition, and results of operations.
  • We face a number of risks related to our income taxes in the United States as well as other jurisdictions.
  • Failure to comply with data privacy and security laws could have a material adverse effect on our business.
  • We may incur losses from product liability or other claims that could adversely affect our operating results.
  • We are subject to litigation, investigations, and other legal proceedings relating to our products, customers, competitors, and government regulators that could materially adversely affect our financial condition, divert management’s attention, and harm our business.
  • Use of our products in unapproved circumstances could expose us to liabilities.
  • Our operations are subject to environmental, health, and safety regulations that could result in substantial costs.
  • Climate change, or legal, regulatory or market measures to address climate change, may materially adversely affect our financial condition and business operations.
  • We are subject to risks arising from concerns and/or regulatory actions relating to animal-borne illnesses, including “mad cow disease.”

Legal proceedings

Please see Note 20 to our Consolidated Financial Statements in this Annual Report for a description of our legal proceedings, which is incorporated by reference herein.

We are subject to various environmental laws and regulations both within and outside of the United States. Our operations, like those of other medical device companies, involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes. While it is difficult to quantify the potential impact of continuing compliance with environmental protection laws, management believes that such compliance will not have a material impact on our financial results. Our threshold for disclosing material environmental legal proceedings involving a governmental authority where potential monetary sanctions are involved is $1 million.

The opening of Item 3, Legal Proceedings.17

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
    SEC EDGAROther events
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89